CIM24SAPP1-I-14

 

CIM24SAPP1-I-14 is a high-yielding, intermediate-maturing maize hybrid with white grain and drought tolerance, that is NUE and resistant to GLS, TLB, ear rots, and MSV, suitable for food use in tropical, rainfed, dry/wet mid-altitude and transition ecologies in southern Africa and similar agroecologies.   General Information   Target region Southern Africa   Adaptation/Agroecological zone 400-1800 masl   Type of product Three-way cross hybrid   Year first announced 2025         Grain Characteristics   Grain color White       Grain texture Semi- dent Grain Yield       Grain yield under optimum conditions 11.03 t/ha   Biotic Stress Performance Grain yield under managed drought 2.75 t/ha   Turcicum leaf blight (TLB) (1-9)* 3.70 Grain yield under low nitrogen 2.75 t/ha   Grey leaf spot (GLS) (1-9)* 3.10 Grian Yield on-farm (moderate stress) 5.34 t/ha   Maize Streak Virus (MSV) (1-9)* 2.30 Grain Yield on-farm (severe stress) 2.10  t/ha   Ear rots 6.00%       *Diseases are scored on a 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible. Agronomic Characteristics     Maturity group Intermediate       50% anthesis 64 DAP   Seed Production Characteristics   870   Single-cross female parent yield 11.61 t/ha Anthesis-silking interval 1.08 Days   Male parent yield 3.83 t/ha Plant height 243 cm   Nicking -1.1 Ear height 126 cm       Ears per plant 1.02   Comments Ear position (ratio) 0.52   Product information is based on data from CIMMYT Southern Africa 2024 Stage 4 and 2024 Stage 5 Trials. Actual performance will vary depending on a number of agronomic and environmental factors.

Abbreviations:
DAP = days after planting
GLS = Grey Leaf Spot
masl = meters above sea level
MSV= Maize Streak Virus
NUE = Nitrogen Use Efficient
TLB = Turcicum Leaf Blight Bad husk cover 7.50   Ear aspect (1-5)* 2.70   Root lodging 7.49%   Stalk lodging 2.08%   *Ear aspect is scored on 1-5 scale, where 1 = desirable and 5 = undesirable characteristics           Further Links   Full Product Announcement
(including trial results summary and site information)